NCT06569667 Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
| NCT ID | NCT06569667 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Friends Research Institute, Inc. |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 292 participants |
| Start Date | 2025-03-28 |
| Primary Completion | 2025-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 292 participants in total. It began in 2025-03-28 with a primary completion date of 2025-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Black and Latinx people who use opioids are disproportionately impacted by opioid overdose deaths. The proposed study assesses the efficacy of an open source, multimodal artificial intelligence-driven texting tool combined with peer recovery coach-supported text contact that delivers social services, stigma reduction, health habitus, and patient navigation content addressing social determinants of health to enhance receipt of buprenorphine in primary care among emergency department-enrolled Black / Latinx people who use opioids.
Eligibility Criteria
Inclusion Criteria: 1. ≥18 years of age; 2. fluent in English and/or Spanish; 3. self-reported non-prescription opioid use \<30 days prior to consent; 4. provision of informed consent; 5. planned stay in NYC ≥12 month; 6. self-identified Black and/or Latinx race/ethnicity; 7. positive urine toxicology for opioids per EMR records; 8. diagnosis of OUD per the Diagnostic and Statistical Manual of Mental Disorders-5 9. self-reported interest in initiating buprenorphine in primary care 10. must have a mobile phone data plan. Exclusion Criteria: 1. inability to comprehend text content written at a 3rd grade reading level; 2. physical or visual disability preventing mobile phone use; 3. self-reported receipt of medications for OUD in past 30 days.
Contact & Investigator
Babak Tofighi, MSc, MD
PRINCIPAL INVESTIGATOR
Friends Research Institute, Inc.
Frequently Asked Questions
Who can join the NCT06569667 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06569667 currently recruiting?
Yes, NCT06569667 is actively recruiting participants. Contact the research team at babak.tofighi@nki.rfmh.org for enrollment information.
Where is the NCT06569667 trial being conducted?
This trial is being conducted at The Bronx, United States.
Who is sponsoring the NCT06569667 clinical trial?
NCT06569667 is sponsored by Friends Research Institute, Inc.. The principal investigator is Babak Tofighi, MSc, MD at Friends Research Institute, Inc.. The trial plans to enroll 292 participants.